JP2018522854A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522854A5
JP2018522854A5 JP2017566077A JP2017566077A JP2018522854A5 JP 2018522854 A5 JP2018522854 A5 JP 2018522854A5 JP 2017566077 A JP2017566077 A JP 2017566077A JP 2017566077 A JP2017566077 A JP 2017566077A JP 2018522854 A5 JP2018522854 A5 JP 2018522854A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
oral pharmaceutical
composition according
pharmaceutically acceptable
acceptable carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017566077A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522854A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/038822 external-priority patent/WO2016210003A2/en
Publication of JP2018522854A publication Critical patent/JP2018522854A/ja
Publication of JP2018522854A5 publication Critical patent/JP2018522854A5/ja
Pending legal-status Critical Current

Links

JP2017566077A 2015-06-22 2016-06-22 １７−ヒドロキシプロゲステロンエステル含有経口組成物及び関連方法 Pending JP2018522854A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562183031P 2015-06-22 2015-06-22
US62/183,031 2015-06-22
US201662295951P 2016-02-16 2016-02-16
US62/295,951 2016-02-16
PCT/US2016/038822 WO2016210003A2 (en) 2015-06-22 2016-06-22 17-hydroxyprogesterone ester-containing oral compositions and related methods

Publications (2)

Publication Number Publication Date
JP2018522854A JP2018522854A (ja) 2018-08-16
JP2018522854A5 true JP2018522854A5 (enExample) 2019-07-25

Family

ID=57586205

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017566077A Pending JP2018522854A (ja) 2015-06-22 2016-06-22 １７−ヒドロキシプロゲステロンエステル含有経口組成物及び関連方法

Country Status (12)

Country Link
US (3) US20170035781A1 (enExample)
EP (1) EP3310359B1 (enExample)
JP (1) JP2018522854A (enExample)
CN (1) CN107847506A (enExample)
AU (1) AU2016284459B2 (enExample)
BR (1) BR112017027688A2 (enExample)
ES (1) ES3005883T3 (enExample)
IL (1) IL256493A (enExample)
MX (1) MX2017016823A (enExample)
PH (1) PH12017502416A1 (enExample)
WO (1) WO2016210003A2 (enExample)
ZA (1) ZA201801692B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3050082A1 (en) 2016-04-04 2017-10-12 Omeza LLC Fish oil topical composition
PE20211285A1 (es) * 2018-11-27 2021-07-19 Bayer Ag Proceso para la produccion de formas farmaceuticas que contienen inhibidores de los canales task-1 y task-3 y su uso para la terapia de trastornos respiratorios
CN109662953B (zh) * 2019-02-18 2022-05-10 威海金思力生物科技股份有限公司 一种维生素d软胶囊及其制作方法
WO2021081276A1 (en) * 2019-10-23 2021-04-29 Slayback Pharma Llc Stable pharmaceutical compositions containing estradiol and progesterone for oral administration
CN111135153B (zh) * 2020-01-21 2025-08-19 安士制药（中山）有限公司 一种熊去氧胆酸胶囊及其制备方法
CN113616660A (zh) * 2020-05-07 2021-11-09 深圳埃格林医药有限公司 孕激素制剂及其用途
JP2024541958A (ja) * 2020-10-27 2024-11-13 リポシン，インク． カプロン酸ヒドロキシプロゲステロン組成物および早産予防における使用の方法
US11370811B1 (en) 2020-11-20 2022-06-28 Lipocine Inc. (17-)-3-oxoandrost-4-en-17-yl dodecanoate compositions and methods of preparation and use
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
IT202100013898A1 (it) * 2021-05-27 2022-11-27 Hulka S R L Composizione comprendente un estere di alfa-tocoferolo per la riduzione del rischio di parto pretermine
CN116077416B (zh) * 2021-11-05 2024-12-06 深圳埃格林医药有限公司 一种包含孕激素的口服制剂及制备方法和应用
WO2024023173A1 (en) * 2022-07-27 2024-02-01 Ipsico Ug Solid pharmaceutical dosage form comprising a bcs class ii drug and a method for producing the same
US12186327B2 (en) 2022-08-29 2025-01-07 Lipocine Inc. Oral allopregnanolone compositions and methods of use
US20250064897A1 (en) * 2023-08-21 2025-02-27 Cmpd Licensing, Llc Topical administration of glp-1 receptor agonists

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3164520A (en) 1962-10-29 1965-01-05 Olin Mathieson Injectable steroid compositions containing at least 75% benzyl benzoate
NL151903B (nl) 1965-03-24 1977-01-17 Schering Ag Werkwijze ter bereiding van een injectievloeistof door een steroid op te lossen in een mengsel van ricinusolie en benzylbenzoaat.
FR2408345A1 (fr) 1976-11-30 1979-06-08 Besins Jean Louis Nouvelle composition a action anti-conceptionnelle
US4230702A (en) 1978-01-09 1980-10-28 Kali-Chemie Pharma Gmbh Readily enterally absorbable pharmaceutical compositions of per se poorly enterally absorbable pharmacologically active agents
US4439432A (en) 1982-03-22 1984-03-27 Peat Raymond F Treatment of progesterone deficiency and related conditions with a stable composition of progesterone and tocopherols
US5314882A (en) 1984-01-03 1994-05-24 International Foundation For Biochemical Endocrinology Method for promoting growth and improved meat quality in meat producing animals with female steroidal hormones
US5140021A (en) 1986-04-16 1992-08-18 Genesis Systems Corporation Method and dosage form for treatment of premenstrual syndrome
GB8730011D0 (en) 1987-12-23 1988-02-03 Smithkline Dauelsberg Pharmaceutical compositions
AU5157590A (en) 1989-02-06 1990-08-24 Abbott Laboratories Pharmaceutical compositions for oral administration
IT1252867B (it) 1991-12-31 1995-06-28 Gentili Ist Spa Composizioni farmaceutiche contenenti progesterone ad elevata biodisponibilita'
DK95093D0 (da) 1993-08-20 1993-08-20 Novo Nordisk As Farmaceutisk formulering indeholdende et hormon
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5633011A (en) 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
ES2233947T3 (es) 1994-08-23 2005-06-16 Deutsche Gelatine-Fabriken Stoess Ag Empleo de colageno hidrolizado, de sabor neutro, y agente que lo contiene.
DE19718012C1 (de) 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
DE19739916C2 (de) 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
FR2772617B1 (fr) 1997-12-19 2001-03-09 Besins Iscovesco Lab Comprime de progesterone et son procede de preparation
FR2775599B1 (fr) 1998-03-09 2001-08-17 Besins Iscovesco Lab Composition pharmaceutique a base de progesterone naturelle de synthese et d'oestradiol et son procede de preparation
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6214815B1 (en) 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB9907715D0 (en) 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20020131988A1 (en) 1999-12-16 2002-09-19 Foster Todd P. Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
US6544553B1 (en) 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
US20040022862A1 (en) 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
FR2818905A1 (fr) 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
FR2821555B1 (fr) 2001-03-01 2003-05-16 Besins Int Lab Progestatif co-micronise avec un tensioactif, composition pharmaceutique le comprenant, leurs procedes de fabrication et leurs utilisations
FR2832065B1 (fr) 2001-11-13 2004-11-05 Besins Int Belgique Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations
CN1622810A (zh) 2002-03-14 2005-06-01 华生制药公司 孕酮口服药物传输系统
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
CN1231210C (zh) 2002-08-20 2005-12-14 杭州容立医药科技有限公司 黄体酮胶囊组合物及其制备方法
JP2005538150A (ja) 2002-08-28 2005-12-15 キャスパー，ロバート エストロゲン補充療法
EP1551415B1 (en) 2002-09-05 2009-12-23 Pantarhei Bioscience B.V. Oral pharmaceutical composition comprising 15-hydroxytestosterone and its analogues
JP2004155780A (ja) 2002-10-16 2004-06-03 Taisho Pharmaceut Co Ltd 生活習慣病改善剤組成物
SI1575569T1 (sl) 2002-12-13 2010-12-31 Durect Corp Oralni sistem dostave zdravila, ki obsega visokoviskozne tekoče nosilne materiale
CN1282459C (zh) 2002-12-24 2006-11-01 上海医药工业研究院 黄体酮胶丸及制备方法
ATE553378T1 (de) * 2003-02-06 2012-04-15 Hologic Inc Screening und behandlungsverfahren zur vorbeugung von frühgeburten
GB0305941D0 (en) 2003-03-14 2003-04-23 Camurus Ab Composition
CN1299686C (zh) 2003-04-03 2007-02-14 上海医药工业研究院 黄体酮半固体骨架制剂的组合物
CN1623550A (zh) * 2003-12-04 2005-06-08 张伟 己酸羟孕酮口服制剂和用途
JP2007516259A (ja) 2003-12-09 2007-06-21 メッドクリスタルフォームズ、エルエルシー 活性剤との混合相共結晶の調製方法
US7569560B2 (en) 2004-03-19 2009-08-04 Warner Chilcott Company Llc Extended cycle multiphasic oral contraceptive method
GT200500186A (es) 2004-07-07 2006-03-02 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
US7473687B2 (en) 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
US8663681B2 (en) 2005-05-26 2014-03-04 Teva Women's Health, Inc. Oral dosage forms comprising progesterone and methods of making and using the same
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
PL2200588T3 (pl) 2007-09-25 2019-09-30 Solubest Ltd. Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania
CA2744906A1 (en) 2007-11-29 2009-06-04 Gregg A. Jackson Progesterone-containing compositions and devices
WO2010117873A2 (en) 2009-04-06 2010-10-14 Banner Pharmacaps, Inc. Progesterone solutions for increased bioavailability
US20120270747A1 (en) 2009-10-29 2012-10-25 The Trustees Of The University Of Pennsylvania Method of predicting risk of pre-term birth
US20110152840A1 (en) 2009-12-23 2011-06-23 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
US20110262502A1 (en) * 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
WO2011112747A1 (en) 2010-03-09 2011-09-15 Catholic Healthcare West Methods for inhibiting preterm labor and uterine contractility disorders and preventing cervical ripening
US20110312928A1 (en) 2010-06-18 2011-12-22 Lipocine Inc. Progesterone Containing Oral Dosage Forms and Related Methods
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
US20110312927A1 (en) 2010-06-18 2011-12-22 Satish Kumar Nachaegari Progesterone Containing Oral Dosage Forms and Related Methods
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods

Similar Documents

Publication Publication Date Title
JP2018522854A5 (enExample)
JP3382940B2 (ja) 中枢ドパミン欠乏状態を治療するための経口投与可能な医薬製剤
EP3313408B1 (en) Drospirenone-based contraceptive for a female patient affected with excess weight
WO2012055840A1 (en) Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders
EA028680B1 (ru) Фармацевтическая композиция, содержащая дроспиренон, и набор для предупреждения зачатия
CA2926073A1 (en) Progesterone containing oral dosage forms and kits
CN102458386A (zh) 用于紧急避孕的药物组合物
US20120053160A1 (en) Dosage Form for Hormonal Contraception
TW201919632A (zh) 治療子宮內膜異位症、子宮纖維瘤、多囊性卵巢症候群或子宮腺肌症之醫藥調配物
KR20230005239A (ko) 경구 투여용 신규한 지연 방출 조성물
TWI351960B (en) Multiphase product for contraception based on a na
JP6254605B2 (ja) 「オンデマンド」避妊のためのレボノルゲストレルおよびｃｏｘ阻害剤を含む医薬組成物の使用および投与計画
HU212428B (en) Process to prepare pharmaceutical compositions containing gemfibrozyl
NZ739324A (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
NZ739324B2 (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
US20170173045A1 (en) Misoprostol Dispersible Tablet
ES2777886T3 (es) Composición farmacéutica que comprende drospirenona y kit anticonceptivo
AU2015287186A1 (en) Misoprostol dispersible tablet
Saini et al. Comparative effectiveness of simultaneous administration of mifepristone and misoprostol versus interval regimen of mifepristone followed by misoprostol 12 hours apart in second trimester medical abortion
CN106265694A (zh) 用于过重女性患者的基于屈螺酮的避孕药
Apter et al. Pharmacokinetics (PK) and effect on ovarian and cervical function of two low-dose levonorgestrel-releasing intrauterine systems (LNG-IUSS): results of randomized, phase II and III studies
CONTRACEPTIVE Prescribing Information
Contraceptive et al. PrOVRAL® 21
Yuzpe Very low doses of mifepristone were as effective for emergency contraception as the higher dose
OA18512A (en) Drospirenone-based contraceptive for a female patient affected with excess weight.